Phase II Study of Gemcitabine Plus Paclitaxel in Metastatic Breast Cancer Patients with Prior Anthracycline Exposure

References

• Bergh, J.; Jonsson, P E.; Glimelius, B.; Nygren, P. A systematic overview of chemotherapy effects in breast cancer.Acta Oncol. 2001, 40 (2-3), 253–281. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Hortobagyi, G N. Treatment of breast cancer.N. Engl. J. Med. 1998, 339 (14), 974–984. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Crown, J.; Dieras, V.; Kaufmann, M.; von Minckwitz, G.; Kaye, S.; , et al. Chemotherapy for metastatic breast cancer-report of a European expert panel.Lancet Oncol. 2002, 3 (12), 719–727. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Tripathy, D. Overview: gemcitabine as single-agent therapy for advanced breast cancer.Clin. Breast Cancer 2002, 3 (Suppl. 1), 8–11. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Blackstein, M.; Vogel, C L.; Ambinder, R.; Cowan, J.; Iglesias, J.; Melemed, A. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial.Oncology 2002, 62 (1), 2–8. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Possinger, K.; Kaufmann, M.; Coleman, R.; Stuart, N S.; , et al. Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer.Anti-Cancer Drugs 1999, 10 (2), 155–162. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Gerson, R.; Serrano-O, A.; Villalobos, A.; Ortiz, C.; Sánchez-Forgach, E (2000) . In Gemcitabine response in advanced breast cancer in relation to ýmmunohistochemical factors, Proceedings of the American Society of Clinical Oncology Annual Meeting, New Orleans, USA, May 20–23, 2000; American Society of Clinical Oncology: Alexandria, ; 145a.
   Google Scholar
• Spielmann, M.; Llombart-Cussac, A.; Kala, S.; Espie, M.; , et al. Single-agent gemcitabine is active in previously treated metastatic breast cancer.Oncology 2001, 60 (4), 303–307. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Schmid, P.; Akrivakis, K.; Flath, B.; Grosse, Y.; Sezer, O.; Mergenthaler, H G.; Possinger, K. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer.Anti-Cancer Drugs 1999, 10 (7), 625–631. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Valerio, M R.; Cicero, G.; Armata, M G.; Bajardi, E.; Crosta, A.; , et al (2001) . In Gemcitabine (G) in Pretreated Breast Cancer (BC), Proceedings of the American Society of Clinical Oncology Annual Meeting, San Francisco, USA, May 12–15, 2001; American Society of Clinical Oncology: Alexandria, ; 51b.
   Google Scholar
• Brodowicz, T.; Kostler, W.; Moslinger, R.; Tomek, S.; Vaclavik, I.; , et al. Single agent gemcitabine as second- and third-line treatment in metastatic breast cancer.Breast 2000, 9 (6), 338–342. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kaplan, E L.; Meier, P. Nonparametric estimation from incomplete observations.J. Am. Stat. Assoc. 1959, 53, 457–481. [CSA]
   Web of Science ®Google Scholar
• Cox, D R. The Analysis of Binary Data; Methuen: London, 1970.
   Google Scholar
• O'Shaughnessy, J.; Nag, S.; Calderillo-Ruiz, G.; Jordaan, J.; Llombart, A.; , et al (2003) . In Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): interim results of a global phase III study, Proceedings of the American Society of Clinical Oncology Annual Meeting, Chicago, USA, May 31–Jun. 3, 2003; American Society of Clinical Oncology: Alexandria, ; 7a.
   Google Scholar
• Nabholtz, J M.; Senn, H J.; Bezwoda, W R.; Melnychuk, D.; Deschenes, L.; , et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group.J. Clin. Oncol. 1999, 17 (5), 1413–1424. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Sjostrom, J.; Blomqvist, C.; Mouridsen, H.; Pluzanska, A.; Ottosson-Lonn, S.; , et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.Eur. J. Cancer 1999, 35 (8), 1194–1201. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bonneterre, J.; Roche, H.; Monnier, A.; Guastalla, J P.; Namer, M.; Fargeot, P.; Assadourian, S. Docetaxel vs. 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure.Br. J. Cancer 2002, 87 (11), 1210–1215. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy, J.; Miles, D.; Vukelja, S.; Moiseyenko, V.; Ayoub, J P.; , et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.J. Clin. Oncol. 2002, 20 (12), 2812–2823. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Holmes, F A.; Walters, R S.; Theriault, R L.; Forman, A D.; Newton, L K.; , et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.J. Natl. Cancer Inst. 1991, 83 (24), 1797–1805. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Holmes, F A.; Valero, V.; Walters, R S.; Theriault, R L.; Booser, D J.; , et al. The M. D. Anderson Cancer Center experience with taxol in metastatic breast cancer.J. Natl. Cancer Inst. Monographs 1993, 15, 161–169. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Seidman, A D.; Reichman, B S.; Crown, J P.; Yao, T J.; , et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response.J. Clin. Oncol. 1995, 13 (5), 1152–1159. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Abrams, J S.; Vena, D A.; Baltz, J.; Adams, J.; Montello, M.; , et al. Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial.J. Clin. Oncol. 1995, 13 (8), 2056–2065. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Nabholtz, J M.; Gelmon, K.; Bontenbal, M.; Spielmann, M.; Catimel, G.; , et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.J. Clin. Oncol. 1996, 14 (6), 1858–1867. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Rinaldi, D A.; Lormand, N A.; Brierre, J E.; Cole, J L.; Stagg, M P.; , et al. Phase I trial of gemcitabine, administered as a standard and constant dose-rate infusion, in combination with paclitaxel in patients with advanced solid tumors (LOA-2).Am. J. Clin. Oncol. 2002, 25 (5), 523–527. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Einhorn, L.; Raghavan, D.; Kindler, H.; Gordon, M.; Fox, S.; Meyers, T.; Sandler, A A (1998) . In Phase I trial of gemcitabine plus paclitaxel combination therapy in patients with refractory solid tumors, Proceedings of the American Society of Clinical Oncology Annual Meeting, CaliforniaUSA, May 16–19, 1998; American Society of Clinical Oncology: Alexandria, ; 207a.
   Google Scholar
• Sanchez-Rovira, P.; Medina, M B.; Mohendano, N.; Jaen, A.; Porras, I.; Gonzalez, E.; Fernandez, M.; Lozano, A. Results from a phase II study of gemcitabine in combination with paclitaxel in metastatic breast cancer.Ann. Oncol. 1998, 9 (Suppl. 4), 77. [CSA]
   Google Scholar
• Murad, A M.; Guimaraes, R C.; Aragao, B C.; Scalabrini-Neto, A O.; Rodrigues, V H.; Garcia, R. Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer.Am. J. Clin. Oncol. 2001, 24 (3), 264–269. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Colomer, R.; Llombart-Cussac, A.; Lluch, A.; Barnadas, A.; Ojeda, B.; , et al. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain.Ann. Oncol. 2004, 15 (2), 201–206. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar